Roche Holding is under pressure to impress investors with its pipeline after cancer drug Avastin and arthritis treatment ocrelizumab missed clinical-trial goals. Michael Nawrath, an analyst at Zuercher Kantonalbank, said the company's stock "will be under pressure" if its experimental medicines fail to meet expectations at a time when "the market is assessing its potential according to the higher multiples used for biotechs."

Related Summaries